Abstract
Desmoplastic small round cell tumor (DSRCT) is a rare and aggressive cancer that typically arises in teenage boys. As a result of its low prevalence, there have been few studies of its treatment and impact on survival. Here, we report the case of a patient who was refractory to multiple drugs but remains stable with trabectedin. To our knowledge, this is the first published report that supports antitumoral activity of trabectedin in DSRCT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stuart-Buttle CE, Smart CJ, Pritchard S, Martin D, Welch IM. Desmoplastic small round cell tumour: a review of literature and treatment options. Surg Oncol. 2008;17(2):107–12.
Tejerina González E, Corbacho Cuevas C, López García A, Bellas C, Sánchez V, Sánchez Ruiz A, de Álava E, Sanz E. Tumor intraabdominal desmoplásico de células pequeñas y redondas. Revisión de la literatura a propósito de un caso con estudio citológico, histopatológico, inmunohistoquímico y molecular. Oncología. 2007;30(1):25–31.
Landayi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumors. Cancer Res. 1994;54:2837–40.
Hassan I, et al. Intraabdominal desmoplastic small round cell tumours—a diagnostic and therapeutic challenge. Cancer. 2005;104(6):1264–70.
Livaditi E, Mavridis G, Soutis M, et al. Diffuse intraabdominal desmoplastic small round cell tumour: a ten-year experience. Eur J Pediatr Surg. 2006;16(6):423–7.
Herrero AB, Martín-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66(16):8155–62.
Grosso F, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595–602.
Grosso F, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009;20(8):1439–44.
Bonfanti M, La Valle E, Fernández Sousa-Faro JM, Faircloth G, Caretti G, Mantonvani R, D’Incalci M. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des. 1999;14:179–86.
Forni C, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8(2):449–57.
Tavecchio M, et al. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach. Cell Prolif. 2007;40:885–904.
Tavecchio M, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer. 2008;44:609–18.
Soares DG, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. PNAS. 2007;104(32):13062–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
López-González, A., Cantos, B., Tejerina, E. et al. Activity of trabectidin in desmoplastic small round cell tumor. Med Oncol 28 (Suppl 1), 644–646 (2011). https://doi.org/10.1007/s12032-010-9687-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-010-9687-9